Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
85650-52-8
Molecular formula
C17H19N3
Molecular weight
265.35 g/mol
Drug class
Tetracyclic antidepressantnoradrenergic and specific serotonergic antidepressant (NaSSA)
Mechanism of action
The mechanism in major depressive disorder is not fully understood. Mirtazapine antagonises central presynaptic alpha-2 adrenergic autoreceptors and heteroreceptors, potentially increasing noradrenergic and serotonergic neurotransmission; it also antagonises 5-HT2, 5-HT3 and H1 receptors.
Indications / reported uses
Treatment of major depressive disorder in adults; the exact contribution of noradrenergic and serotonergic actions to clinical response is not fully established
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Mirtazapine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mirtazapine Permitted Daily Exposure (PDE) report (the Mirtazapine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mirtazapine Occupational Exposure Limit (OEL) report (the Mirtazapine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.